Cargando…

Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use

Intravenous efgartigimod alfa (also known as efgartigimod alfa-fcab in the USA; Vyvgart(®)) is the first neonatal Fc receptor antagonist approved in several countries worldwide, including the USA and EU for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine rec...

Descripción completa

Detalles Bibliográficos
Autor principal: Heo, Young-A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212825/
https://www.ncbi.nlm.nih.gov/pubmed/37000339
http://dx.doi.org/10.1007/s40263-023-01000-z